Notwithstanding different setbacks, several MDM2 inhibitors have now progressed into late-phase medical advancement. New strategies have also been made to improve the efficacy of MDM2 inhibitors and to mitigate their on-focus on toxicity. On this overview, we summarize the progress and issues in the development of the MDM2 focused therapy. https://andersonbvngw.mybjjblog.com/abbv-744-no-further-a-mystery-45024356